Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK 10.32
+0.41 (4.14%)
At close: Feb 5, 2026
Xbrane Biopharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 259.7 | 198.72 | 238.73 | 57.62 | 10.71 | - |
| 259.7 | 198.72 | 238.73 | 57.62 | 10.71 | - | |
Revenue Growth (YoY) | 74.08% | -16.76% | 314.33% | 438.03% | - | - |
Cost of Revenue | 60.1 | 18.23 | 203.34 | - | - | - |
Gross Profit | 199.6 | 180.5 | 35.39 | 57.62 | 10.71 | - |
Selling, General & Admin | 46.82 | 40.11 | 40.03 | 31.54 | 31.4 | 26.51 |
Research & Development | 228.58 | 312.89 | 305.78 | 199.65 | 160.62 | 197.28 |
Other Operating Expenses | 27.32 | 30.54 | -13.71 | -20.91 | -4.85 | -7.14 |
Operating Expenses | 302.72 | 383.54 | 332.11 | 210.27 | 187.17 | 216.65 |
Operating Income | -103.12 | -203.04 | -296.72 | -152.65 | -176.46 | -216.65 |
Interest Expense | -24.21 | -33.63 | -18.5 | -2.58 | -2.64 | -0.69 |
Interest & Investment Income | 0.5 | 0.5 | 2.41 | 0.3 | - | - |
Currency Exchange Gain (Loss) | -12.24 | -14.87 | -9.15 | -13.56 | -4.13 | -0.79 |
Other Non Operating Income (Expenses) | -2.39 | -2.39 | -0.06 | -0.01 | -0.01 | - |
Pretax Income | -141.46 | -253.43 | -322.03 | -168.51 | -183.23 | -218.13 |
Income Tax Expense | 13.82 | 11.59 | - | - | - | - |
Earnings From Continuing Operations | -155.28 | -265.02 | -322.03 | -168.51 | -183.23 | -218.13 |
Earnings From Discontinued Operations | 255.81 | -1.2 | -66.14 | -4 | -5.15 | -7.9 |
Net Income | 100.52 | -266.22 | -388.17 | -172.51 | -188.38 | -226.03 |
Net Income to Common | 100.52 | -266.22 | -388.17 | -172.51 | -188.38 | -226.03 |
Shares Outstanding (Basic) | 19 | 10 | 0 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 19 | 10 | 0 | 0 | 0 | 0 |
Shares Change (YoY) | 171.10% | 4184.97% | 12.26% | 8.38% | 30.25% | 61.86% |
EPS (Basic) | 5.42 | -27.06 | -1690.32 | -843.34 | -998.04 | -1559.80 |
EPS (Diluted) | 4.51 | -27.62 | -1690.32 | -843.34 | -998.54 | -1560.00 |
Free Cash Flow | -199.18 | -134.23 | -413.47 | -205.53 | -247.29 | -242.26 |
Free Cash Flow Per Share | -10.75 | -13.64 | -1800.48 | -1004.76 | -1310.16 | -1671.85 |
Gross Margin | 76.86% | 90.83% | 14.82% | 100.00% | 100.00% | - |
Operating Margin | -39.71% | -102.17% | -124.29% | -264.94% | -1647.75% | - |
Profit Margin | 38.71% | -133.97% | -162.60% | -299.41% | -1759.04% | - |
Free Cash Flow Margin | -76.70% | -67.55% | -173.20% | -356.72% | -2309.16% | - |
EBITDA | -108.72 | -193.86 | -287.62 | -145.21 | -171.93 | -214.07 |
EBITDA Margin | -41.86% | -97.55% | -120.48% | -252.03% | - | - |
D&A For EBITDA | -5.6 | 9.18 | 9.1 | 7.44 | 4.53 | 2.57 |
EBIT | -103.12 | -203.04 | -296.72 | -152.65 | -176.46 | -216.65 |
EBIT Margin | -39.71% | -102.17% | -124.29% | -264.94% | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.